vs

Side-by-side financial comparison of InMode Ltd. (INMD) and LivaNova PLC (LIVN). Click either name above to swap in a different company.

LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $93.2K, roughly 3874.0× InMode Ltd.). InMode Ltd. runs the higher net margin — 23.5% vs 8.6%, a 14.9% gap on every dollar of revenue.

Mode Media, Inc., was a digital lifestyle media company operating a suite of websites where content was produced by anyone but reviewed by professional editors prior to publishing. In 2013, Mode Media had a valuation of about $1 billion as the company prepped for an IPO. In 2015, Mode Media had grown to over $100 million in revenue, primarily from providing native content, branded video and digital advertising to large brands but had over $100 million in expenses.

LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".

INMD vs LIVN — Head-to-Head

Bigger by revenue
LIVN
LIVN
3874.0× larger
LIVN
$360.9M
$93.2K
INMD
Higher net margin
INMD
INMD
14.9% more per $
INMD
23.5%
8.6%
LIVN

Income Statement — Q3 2025 vs Q4 2025

Metric
INMD
INMD
LIVN
LIVN
Revenue
$93.2K
$360.9M
Net Profit
$21.9K
$30.9M
Gross Margin
77.6%
65.2%
Operating Margin
11.8%
Net Margin
23.5%
8.6%
Revenue YoY
12.1%
Net Profit YoY
-44.7%
EPS (diluted)
$0.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INMD
INMD
LIVN
LIVN
Q4 25
$360.9M
Q3 25
$93.2K
$357.8M
Q2 25
$95.6K
$352.5M
Q1 25
$77.9K
$316.9M
Q4 24
$321.8M
Q3 24
$130.2K
$318.1M
Q2 24
$86.4K
$318.6M
Q1 24
$80.3K
$294.9M
Net Profit
INMD
INMD
LIVN
LIVN
Q4 25
$30.9M
Q3 25
$21.9K
$26.8M
Q2 25
$26.7K
$27.2M
Q1 25
$18.2K
$-327.3M
Q4 24
$55.9M
Q3 24
$51.0K
$33.0M
Q2 24
$23.8K
$16.3M
Q1 24
$23.7K
$-41.9M
Gross Margin
INMD
INMD
LIVN
LIVN
Q4 25
65.2%
Q3 25
77.6%
68.4%
Q2 25
80.0%
67.8%
Q1 25
78.2%
69.7%
Q4 24
68.2%
Q3 24
81.5%
70.8%
Q2 24
80.2%
68.7%
Q1 24
79.6%
70.3%
Operating Margin
INMD
INMD
LIVN
LIVN
Q4 25
11.8%
Q3 25
15.1%
Q2 25
15.4%
Q1 25
15.3%
Q4 24
11.5%
Q3 24
11.2%
Q2 24
12.6%
Q1 24
5.5%
Net Margin
INMD
INMD
LIVN
LIVN
Q4 25
8.6%
Q3 25
23.5%
7.5%
Q2 25
28.0%
7.7%
Q1 25
23.4%
-103.3%
Q4 24
17.4%
Q3 24
39.2%
10.4%
Q2 24
27.6%
5.1%
Q1 24
29.5%
-14.2%
EPS (diluted)
INMD
INMD
LIVN
LIVN
Q4 25
$0.57
Q3 25
$0.49
Q2 25
$0.50
Q1 25
$-6.01
Q4 24
$1.04
Q3 24
$0.60
Q2 24
$0.30
Q1 24
$-0.78

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INMD
INMD
LIVN
LIVN
Cash + ST InvestmentsLiquidity on hand
$155.3K
$635.6M
Total DebtLower is stronger
$376.1M
Stockholders' EquityBook value
$703.8K
$1.2B
Total Assets
$785.7K
$2.6B
Debt / EquityLower = less leverage
0.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INMD
INMD
LIVN
LIVN
Q4 25
$635.6M
Q3 25
$155.3K
$646.1M
Q2 25
$155.3K
$593.6M
Q1 25
$155.3K
$738.4M
Q4 24
$428.9M
Q3 24
$144.4K
$346.4M
Q2 24
$144.4K
$329.2M
Q1 24
$144.4K
$309.2M
Total Debt
INMD
INMD
LIVN
LIVN
Q4 25
$376.1M
Q3 25
$434.5M
Q2 25
$430.6M
Q1 25
$628.2M
Q4 24
$627.0M
Q3 24
$625.5M
Q2 24
$624.5M
Q1 24
$623.8M
Stockholders' Equity
INMD
INMD
LIVN
LIVN
Q4 25
$1.2B
Q3 25
$703.8K
$1.2B
Q2 25
$703.8K
$1.1B
Q1 25
$703.8K
$1.0B
Q4 24
$1.3B
Q3 24
$787.4K
$1.3B
Q2 24
$787.4K
$1.2B
Q1 24
$787.4K
$1.2B
Total Assets
INMD
INMD
LIVN
LIVN
Q4 25
$2.6B
Q3 25
$785.7K
$2.6B
Q2 25
$785.7K
$2.5B
Q1 25
$785.7K
$2.6B
Q4 24
$2.5B
Q3 24
$863.3K
$2.5B
Q2 24
$863.3K
$2.5B
Q1 24
$863.3K
$2.5B
Debt / Equity
INMD
INMD
LIVN
LIVN
Q4 25
0.31×
Q3 25
0.38×
Q2 25
0.38×
Q1 25
0.61×
Q4 24
0.47×
Q3 24
0.48×
Q2 24
0.50×
Q1 24
0.51×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INMD
INMD
LIVN
LIVN
Operating Cash FlowLast quarter
$24.5K
$82.4M
Free Cash FlowOCF − Capex
$50.2M
FCF MarginFCF / Revenue
13.9%
Capex IntensityCapex / Revenue
8.9%
Cash ConversionOCF / Net Profit
1.12×
2.67×
TTM Free Cash FlowTrailing 4 quarters
$173.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INMD
INMD
LIVN
LIVN
Q4 25
$82.4M
Q3 25
$24.5K
$85.1M
Q2 25
$24.1K
$62.9M
Q1 25
$14.0K
$24.0M
Q4 24
$78.7M
Q3 24
$34.0K
$51.0M
Q2 24
$42.1K
$43.4M
Q1 24
$24.1K
$10.0M
Free Cash Flow
INMD
INMD
LIVN
LIVN
Q4 25
$50.2M
Q3 25
$62.2M
Q2 25
$47.8M
Q1 25
$13.2M
Q4 24
$68.3M
Q3 24
$32.8M
Q2 24
$31.2M
Q1 24
$3.6M
FCF Margin
INMD
INMD
LIVN
LIVN
Q4 25
13.9%
Q3 25
17.4%
Q2 25
13.6%
Q1 25
4.2%
Q4 24
21.2%
Q3 24
10.3%
Q2 24
9.8%
Q1 24
1.2%
Capex Intensity
INMD
INMD
LIVN
LIVN
Q4 25
8.9%
Q3 25
6.4%
Q2 25
4.3%
Q1 25
3.4%
Q4 24
3.2%
Q3 24
5.7%
Q2 24
3.8%
Q1 24
2.2%
Cash Conversion
INMD
INMD
LIVN
LIVN
Q4 25
2.67×
Q3 25
1.12×
3.18×
Q2 25
0.90×
2.32×
Q1 25
0.77×
Q4 24
1.41×
Q3 24
0.67×
1.55×
Q2 24
1.77×
2.65×
Q1 24
1.02×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

INMD
INMD

Segment breakdown not available.

LIVN
LIVN

Other$169.4M47%
Neuromodulation Segment$119.7M33%
Cardiopulmonary Segment$71.8M20%

Related Comparisons